{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:35:44Z","timestamp":1791376544185,"version":"4.3.2"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000109","name":"Prostate Cancer Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000109","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","redjournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ijrobp.2024.09.009","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T12:11:58Z","timestamp":1726488718000},"page":"325-330","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Stereotactic Radiation Therapy for Localized Prostate Cancer: 10-Year Outcomes From Three Prospective Trials"],"prefix":"10.1016","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1603-8121","authenticated-orcid":false,"given":"Thomas A.C.","family":"Kennedy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee Loon","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey","family":"Quon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Vesprini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilip","family":"Panjwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasir","family":"Alayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geordi","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Korol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Mamedov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Deabreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4883-1781","authenticated-orcid":false,"given":"Andrew","family":"Loblaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2024.09.009_bib0001","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.clon.2015.01.011","article-title":"Stereotactic body radiotherapy for prostate cancer","volume":"27","author":"Henderson","year":"2015","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2024.09.009_bib0002","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s40258-014-0106-9","article-title":"Systematic review of the cost effectiveness of radiation therapy for prostate cancer from 2003 to 2013","volume":"12","author":"Amin","year":"2014","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.ijrobp.2024.09.009_bib0003","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.radonc.2020.04.039","article-title":"Accelerating prostate stereotactic ablative body radiotherapy: efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT)","volume":"149","author":"Alayed","year":"2020","journal-title":"Radiother Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2024.09.009_bib0004","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.clon.2008.08.006","article-title":"Phase I\/II study of a five-fraction hypofractionated accelerated radiotherapy treatment for low-risk localised prostate cancer: early results of pHART3","volume":"20","author":"Tang","year":"2008","journal-title":"Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.09.009_bib0005","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.radonc.2015.12.020","article-title":"Dose-escalation of five-fraction SABR in prostate cancer: toxicity comparison of two prospective trials","volume":"118","author":"Musunuru","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2024.09.009_bib0006","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2024.09.009_bib0007","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.ijrobp.2023.08.027","article-title":"5-year outcomes from PACE B: an international phase III randomized controlled trial comparing stereotactic body radiotherapy (SBRT) vs. conventionally fractionated or moderately hypo fractionated external beam radiotherapy for localized prostate cancer","volume":"117","author":"van As","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.09.009_bib0008","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2024.09.009_bib0009","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000356115","article-title":"Radiation-induced secondary malignancy in prostate cancer: a systematic review and meta-analysis","volume":"93","author":"Jin","year":"2014","journal-title":"Urol Int"},{"key":"10.1016\/j.ijrobp.2024.09.009_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14740\/wjon996w","article-title":"Radiation-induced malignancies making radiotherapy a \u201ctwo-edged sword\u201d: a review of literature","volume":"8","author":"Singh","year":"2017","journal-title":"World J Oncol"},{"key":"10.1016\/j.ijrobp.2024.09.009_bib0011","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.radonc.2018.02.029","article-title":"Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): a phase 2 randomized trial","volume":"127","author":"Quon","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2024.09.009_bib0012","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/(SICI)1097-0142(19980101)82:1<8::AID-CNCR3>3.0.CO;2-W","article-title":"Sarcoma arising in irradiated bone: report of eleven cases. 1948","volume":"82","author":"Cahan","year":"1998","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ijrobp.2024.09.009_bib0013","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/00949650212847","article-title":"Empirical comparisons between Kaplan-Meier and Nelson-Aalen survival function estimators","volume":"72","author":"Colosimo","year":"2010","journal-title":"J Stat Comput Simul"},{"key":"10.1016\/j.ijrobp.2024.09.009_bib0014","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.ijrobp.2019.03.051","article-title":"Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6,000 patients treated on prospective studies","volume":"104","author":"Jackson","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.09.009_bib0015","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.8006","article-title":"Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer","volume":"2","author":"Kishan","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ijrobp.2024.09.009_bib0016","first-page":"289","article-title":"Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial","volume":"299","author":"D'Amico","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2024.09.009_bib0017","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3389\/fonc.2014.00240","article-title":"Stereotactic body radiotherapy as treatment for organ confined low- and intermediate-risk prostate carcinoma, a 7-year study","volume":"4","author":"Katz","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2024.09.009_bib0018","series-title":"Number and rates of new cases of primary cancer, by cancer type, age group and sex","year":"2024"},{"key":"10.1016\/j.ijrobp.2024.09.009_bib0019","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.radonc.2010.09.012","article-title":"Analysis of second malignancies after modern radiotherapy versus prostatectomy for localized prostate cancer","volume":"98","author":"Huang","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2024.09.009_bib0020","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.radonc.2021.06.023","article-title":"Second malignancy probabilities in prostate cancer patients treated with SBRT and other contemporary radiation techniques","volume":"161","author":"Dee","year":"2021","journal-title":"Radiother Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301624033686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301624033686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T18:18:15Z","timestamp":1736965095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301624033686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0360301624033686"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2024.09.009","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic Radiation Therapy for Localized Prostate Cancer: 10-Year Outcomes From Three Prospective Trials","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2024.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}